SCID-X1 gene therapy - AVAX

Drug Profile

SCID-X1 gene therapy - AVAX

Alternative Names: SCID gene therapy - AVAX; SCID-XI gene therapy

Latest Information Update: 06 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Necker Hospital
  • Developer AVAX Technologies; Necker Hospital
  • Class Gene therapies
  • Mechanism of Action Lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Immunodeficiency disorders

Most Recent Events

  • 06 Feb 2017 Discontinued - Phase-I/II for Immunodeficiency disorders in France (unspecified route)
  • 24 Jan 2005 Suspended - Phase I/II for Immunodeficiency disorders in France (unspecified route)
  • 24 May 2004 Phase I/II trials in Immunodeficiency disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top